Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials

References

• Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014:354250.
   PubMedGoogle Scholar
• Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16.
   PubMed Web of Science ®Google Scholar
• Adamson AS. The economics burden of atopic dermatitis. Adv Exp Med Biol. 2017;1027:79–92.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40(2):84–92.
   PubMed Web of Science ®Google Scholar
• David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Adv Exp Med Biol. 2017;1027:21–37.
   PubMed Web of Science ®Google Scholar
• He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–192.
   PubMed Web of Science ®Google Scholar
• Damsky W, Peterson D, Ramseier J, et al. The emerging role of janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol. 2021;147(3):814–826.
   PubMed Web of Science ®Google Scholar
• Boguniewicz M. Topical treatment of atopic dermatitis. Immunol Allergy Clin North Am. 2004;24(4):631–644. vi–vii.
   PubMed Web of Science ®Google Scholar
• Rajagopalan M, De A, Godse K, et al. Guidelines on management of atopic dermatitis in India: an evidence-based review and an expert consensus. Indian J Dermatol. 2019;64(3):166–181.
   PubMed Web of Science ®Google Scholar
• LePoidevin LM, Lee DE, Shi VY. A comparison of international management guidelines for atopic dermatitis. Pediatr Dermatol. 2019;36(1):36–65.
   PubMed Web of Science ®Google Scholar
• Renert-Yuval Y, Guttman-Yassky E. Monoclonal antibodies for the treatment of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2018;18(4):356–364.
   PubMed Web of Science ®Google Scholar
• Highlights of the prescribing information [cited 2021 Jun 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761055s020lbl.pdf
   Google Scholar
• Cartron AM, Nguyen TH, Roh YS, et al. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality. Clin Exp Dermatol. 2021;46(5):820–824.
   PubMed Web of Science ®Google Scholar
• FDA grants priority review and E.M.A. accepts regulatory submission for Pfizer’s abrocitinib, an oral once-daily jak1 inhibitor, for patients 12 and up with moderate to severe atopic dermatitis. Available from: https://www.pfizer.com/news/press-release/press-release-detail/fda-grants-priority-review-and-ema-accepts-regulatory
   Google Scholar
• Singh R, Heron CE, Ghamrawi RI, et al. Emerging role of janus kinase inhibitors for the treatment of atopic dermatitis. Immunotargets Ther. 2020;9:255–272.
   PubMed Web of Science ®Google Scholar
• Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101–1112.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863–873.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–1379.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE Mono-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–266.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.2. Cochrane; 2021 [updated 2021 Feb]. Available from: www.training.cochrane.org/handbook
   Google Scholar
• Review Manager (RevMan) [Computer program]. Version 5.4, The Cochrane Collaboration; 2020.
   Google Scholar
• Schwarzer G. meta: An R package for meta-analysis; 2007. p. 40–45.
   Google Scholar
• Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis version 3. Englewood, NJ: Biostat; 2013.
   Google Scholar
• . GRADEpro G.D.T. GRADEpro Guideline Development Tool [Software]. McMaster University; 2020 (Developed by Evidence Prime, Inc.). Available from: gradepro.org
   Google Scholar
• Dhadwal G, Albrecht L, Gniadecki R, et al. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section IV: treatment options for the management of atopic dermatitis. J Cutan Med Surg. 2018;22(1_suppl):21S–29S.
   PubMedGoogle Scholar
• Eichenfield LF, Ahluwalia J, Waldman A, et al. Current guidelines for the evaluation and management of atopic dermatitis: a comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. J Allergy Clin Immunol. 2017;139(4S):S49–S57.
   PubMed Web of Science ®Google Scholar
• Futamura M, Leshem YA, Thomas KS, et al. A systematic review of investigator global assessment (I.G.A.) in atopic dermatitis (A.D.) trials: many options, no standards. J Am Acad Dermatol. 2016;74(2):288–294.
   PubMed Web of Science ®Google Scholar
• Simpson E, Bissonnette R, Eichenfield LF, et al. The validated investigator global assessment for atopic dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839–846.
   PubMed Web of Science ®Google Scholar
• Wang FP, Tang XJ, Wei CQ, et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2018;90(2):190–198.
   PubMed Web of Science ®Google Scholar
• Tsai HR, Lu JW, Chen LY, et al. Application of janus kinase inhibitors in atopic dermatitis: an updated systematic review and meta-analysis of clinical trials. J Pers Med. 2021;11(4):279.
   PubMed Web of Science ®Google Scholar
• Rehal B, Armstrong AW, Armstrong A. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985–2010. PLOS One. 2011;6(4):e17520.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–769.
   PubMed Web of Science ®Google Scholar